Delivering clarity
for a better tomorrow
PROSTATENOW™ is a germline test for people who have been diagnosed with prostate cancer or have a family history of prostate cancer or other hereditary cancer disorders.
This test can aid in predicting risk levels associated with cancer progression or disease development, as well as in identifying potential targeted therapy options.

PROSTATENOW™ was developed in collaboration with NorthShore University HealthSystem and is the only commercially available germline panel that incorporates three screening methods (family history, rare pathogenic mutations (RPMs), and genetic risk score (GRS)) for a comprehensive inherited prostate cancer risk assessment.
PROSTATENOW™ is the only test today that assesses
a patient’s risk based on all three methods:
  • Family History (FH)
    Family History (FH) is a common but indirect measurement of inherited risk. Those with a family history of prostate cancer have a 1.5-to-2.5-fold increased risk of developing prostate cancer.
  • Rare Pathogenic Mutations (RPMs)
    Rare Pathogenic Mutations (RPMs) are pathogenic DNA mutations in the coding regions of genes known to be associated with prostate cancer, such as ATM, BRCA2, and CHEK2. RPMs are associated with both an increased risk for developing prostate cancer and more aggressive tumor behavior.
  • Genetic Risk Score (GRS)
    Genetic Risk Score (GRS) is calculated based on analysis of >200 single nucleotide polymorphisms (SNPs) known to be associated with prostate cancer. GRS is used to assess a man’s risk of developing prostate cancer compared to other men in the general population.
PROSTATENOW is the only germline panel that includes genotyping of HSD3B1 1245C, an important biomarker in predicting response to androgen deprivation therapy
(ADT). This common risk allele in HSD3B1 is associated with increased resistance to ADT and patients carrying this variant display shorter time to development of castrate-resistant prostate cancer.
PROSTATENOW provides clinically actionable information for patients who have been diagnosed with or have an increased risk for prostate cancer. In patients with localized disease, PROSTATENOW supplements traditional clinical variables like Gleason score and PSA levels in determining risk for disease progression and can aid in treatment planning. For those with advanced disease, PROSTATENOW can offer insights into treatment response and potential targeted therapies, such as PARP inhibitors. For unaffected men with a family history of prostate cancer, this comprehensive inherited risk assessment can inform decisions regarding prostate cancer screening.
Why should urologists consider PROSTATENOW?
Who benefits from PROSTATENOW?
How do urologists incorporate PROSTATENOW into their practice?
We're here to guide you through the process.
Part of PROSTATENOW includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results.
Most hereditary cancers
This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.
Learn more
Breast cancer
There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW® is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.
Learn more
Colon cancer
LYNCHNOW® is a cost-effective, screening that rapidly detects mutations that causes Lynch syndrome.
Learn more